- Previous Close
2.4800 - Open
2.4900 - Bid 2.3500 x 100
- Ask 2.4300 x 100
- Day's Range
2.3800 - 2.5000 - 52 Week Range
2.3450 - 6.4000 - Volume
200,315 - Avg. Volume
346,808 - Market Cap (intraday)
123.296M - Beta (5Y Monthly) 1.79
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8300 - Earnings Date Mar 3, 2025 - Mar 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.75
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
www.2seventybio.comRecent News: TSVT
View MorePerformance Overview: TSVT
Trailing total returns as of 1/14/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TSVT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TSVT
View MoreValuation Measures
Market Cap
123.30M
Enterprise Value
178.34M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.72
Price/Book (mrq)
0.54
Enterprise Value/Revenue
3.91
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-207.25%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
45.62M
Net Income Avi to Common (ttm)
-94.55M
Diluted EPS (ttm)
-1.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
201.87M
Total Debt/Equity (mrq)
107.07%
Levered Free Cash Flow (ttm)
--